---
title: "Nexgel names Brian Kieser interim CEO, replacing Adam Levy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296531071.md"
description: "Nexgel has appointed Brian Kieser as interim CEO, replacing Adam Levy, effective August 21, 2026. This leadership change coincides with an operational integration push and a broader strategic review overseen by a special board committee. Levy will step down but provide 90 days of transition assistance focusing on knowledge transfer and BioNX Surgical integration. Kieser brings prior experience in integrating BioNX Surgical and strategic planning."
datetime: "2026-08-20T20:06:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296531071.md)
  - [en](https://longbridge.com/en/news/296531071.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296531071.md)
generator: "portal-rs"
---

# Nexgel names Brian Kieser interim CEO, replacing Adam Levy

-   Nexgel named Brian Kieser interim CEO effective Aug. 21, 2026 amid an operational integration push and broader strategic review. \* Kieser previously worked on integrating the BioNX Surgical division, manufacturing transition, commercialization, financing, strategic planning via Sequence Life Science partnership. \* Adam Levy will step down as CEO and leave the company effective Aug. 21, 2026. \* Levy will provide transition assistance for 90 days focused on knowledge transfer, key relationships, BioNX Surgical integration, public reporting support. \* A special board committee for strategic review, chaired by Kevin Harris with Steve Glassman, will oversee restructuring, liquidity, capital structure matters. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexgel Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608201605PRIMZONEFULLFEED9813812) on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NXGL.US](https://longbridge.com/en/quote/NXGL.US.md)
- [NXGLW.US](https://longbridge.com/en/quote/NXGLW.US.md)

## Related News & Research

- [NXGL: Q2 revenue reached $3.69M with a $2.87M net loss; integration and expansion efforts continue](https://longbridge.com/en/news/296106108.md)
- [Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition](https://longbridge.com/en/news/296183101.md)
- [Nex names Brian Kieser interim CEO as Adam R. Levy departs](https://longbridge.com/en/news/296651752.md)
- [Bio-Techne declares Q3 2026 distribution of R$ 0.01 per unit, payable Sept. 10](https://longbridge.com/en/news/296357843.md)
- [AIIR: H1'26 saw resilient revenue and stable Adjusted EBITDA amid disruption, with growth set to accelerate](https://longbridge.com/en/news/296476265.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**